Decrease of prostaglandin I2 binding sites in thyroid cancer

Human hepatocellular cancers show decreased prostaglandin E1 binding capacity

“…A similar alteration of the binding capacity was recently obtained for thyroid cancers with respect to the 3H-PGE1-binding sites (Virgolini et al, 1988a). It is of interest that some authors reported on a more increased PGE1-sensitive adenylate cyclase activity in rat hepatomas (Allen et al, 1971;Bronstad & Christofferson, 1981;Chayoth et al, 1973).…”

“…Furthermore, PGI2 high affinity binding sites were significantly decreased in relation to the degree of differentiation of the cancer (Virgolini et al, 1988a). Since various other groups (Garrity et al, 1983;Nassar et al, 1985;Okumura et al, 1985) investigated the properties of prostaglandin-binding sites in rat hepatic tissue showing important effects of prostaglandins via the mediation of cAMP (Brass & Garrity, 1985;Sweat et al, 1983), and also regulatory mechanisms at the receptor level (Garrity et al, 1987), we investigated prostaglandin E1 (PGE,)-binding sites in normal human hepatic tissue (Virgolini et al, 1988b).…”

Acetylsalicylic acid (ASA) protects the prostaglandin-cAMP-system of human hypernephroma cells against irradiation-induced alterations

“…We have demonstrated in human thyroid cancer (Virgolini et al, 1988) and hepatomas (Virgolini et al, 1989) that the number of PG receptors significantly (P<0.001) correlates with the cellular differentiation of the tumour. In these studies we found that high differentiated cancers seems to possess a higher PG receptor density than do anaplastic or less differentiated cancers.…”

“…However, the half maximal effective doses (ED50) (Virgolini et al, 1988) and E human hepatocellular cancer (Virgolini et al, 1989). We -a Al / (Virgolini et al, 1988(Virgolini et al, , 1989 Bm. : binding capacity in fmol mg-' protein; Kd: (dissociation constant) in nM; not investigated.…”